National Pharmaceutical Pricing Authority

NPPA fixes retail price of 28 drugs, ceiling price of six formulations

The National Pharmaceutical Pricing Authority has revised retail prices of 28 formulations and capped ceiling prices for six drugs under the National List of Essential Medicines

NPPA sets prices for 42 drugs, revises ceiling for 2 formulations

Prices have been fixed for drugs and formulations meant for diabetes, hypertension, heart issues, bacterial infections, allergies, and multivitamins

NPPA under fire for 50% rise in drug prices, panel demands explanation

Parliamentary panel slams drug pricing regulator for hike on 11 drugs used for treating conditions such as asthma, glaucoma, thalassemia, tuberculosis, and mental health disorders

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

The ceiling prices of seven other drugs were revised to include the impact of the 0.00551 per cent increase in drug prices in the National List of Essential Medicines

Essential drug prices stay flat this year, offering relief to consumers

This would come after the price hikes allowed (in line with the change in WPI) in the previous two years were 12.12 per cent (2023) and 10.7 per cent (2022) respectively

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Streamlining trade margins on drugs priced Rs 100 and above likely

Drugs for ailments like chronic kidney disease, some high end antibiotics, anti-virals (anti-infectives), as well as some cancer drugs are likely to be brought under trade margin rationalization first

DOLO-650 makers distributed freebies worth Rs 1,000 cr to doctors: FMRAI

The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India

Natl Pharma Pricing Authority fixes retail prices of 84 drug formulations

Drug pricing regulator NPPA has fixed the retail prices for 84 drug formulations, including those used for treatment of diabetes, headache and high blood pressure. The National Pharmaceutical Pricing Authority (NPPA) has also fixed the prices of formulations indicated to reduce increased cholesterol and triglycerides levels, among others. In exercise of the powers conferred by the Drugs (Prices Control) Order, 2013, the NPPA has fixed the retail prices of the medications, the regulator said in a notification. As per the order, a single tablet of Voglibose and (SR) Metformin Hydrochloride will cost Rs 10.47, excluding GST. Similarly, the price of Paracetamol and Caffeine has been fixed at Rs 2.88 per tablet. Besides, the price of one Rosuvastatin Aspirin and Clopidogrel capsule has been fixed at Rs 13.91. In a separate notification, NPPA said it has extended the revised ceiling price of liquid medical oxygen and oxygen inhalation (medicinal gas) till September 30 this year. The NP

NPPA extends price cap on knee implants by a year to September 2021

A few weeks back, the pricing regulator had extended the price cap by a month after the earlier order validity ended in August

Regulator extends price cap on knee implants by one month till Sept 15

The NPPA had allowed firms to take a 10 per cent hike for their knee implant products last year

More drugs may see price revisions as raw material costs, expenses rise

API prices have gone up by 25-30 per cent for some drugs in recent months

Cipla, Glenmark get NPPA nod for inhaler pricing over 'innovative' quotient

Glenmark had appealed to the pricing regulator in 2016 asking for a differential price for its Digihaler

Govt reviews industry's demands to implement changes in drug price policy

A senior government official said the industry has been requesting for an amendment to allow them to implement the price change from the next batch.

Ceiling prices of 21 key medicines raised by 50%; NPPA invokes DPCO 2013

The prices of APIs have gone up in the range of 5-88%

Health care sector is on a recovery path after muted performance: Icra

The strong performance of the sector is in line with our expectations: Icra

The price of controls

Price caps on sanitary products and hand washes are counterproductive

Syringes, needles being sold at highly inflated prices: NPPA analysis

Insulin syringes 1 ml are being sold at maximum trade margins of 400% with needles and at 287% without needles

Cancer, cardiac among 51 essential drugs under NPPA price cap

Drugs whose ceiling prices have been capped includes colon or rectal cancer treatment drug oxaliplatin

Prices of 18 drugs slashed by up to 23%

The drugs that have come under price revision are for chemotherapy, treating malaria and epilepsy, among others